ME 23ANDME HLDG CO

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

“Seat 16” program allows audiences to share the critically acclaimed film with teens across the country

SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify Ava DuVernay’s new film and the film’s groundbreaking  program. Seat16 allows anyone to gift $16 or more to purchase an ORIGIN movie ticket for a young person who might not otherwise be able to purchase a ticket to the film. For 23 days, 23andMe will donate 100 seats daily to support the program.

ARRAY, the multi-platform arts and social impact collective founded by Ava DuVernay, created the Seat16 initiative to ensure that 10,000 young people across the nation get to experience ORIGIN.

Written, directed, and produced by Academy Award nominee Ava DuVernay, ORIGIN explores the mystery of history, the wonders of romance, and a fight for our future. While investigating the global phenomenon of caste and its dark influence on society, a journalist faces unfathomable personal loss and uncovers the beauty of human resilience. With an expansive cast that includes Academy Award nominee Aunjanue Ellis-Taylor, Jon Bernthal, and Niecy Nash-Betts, the film was inspired by Pulitzer Prize-winning journalist Isabel Wilkerson's novel Caste: The Origin of Our Discontents.

“It’s a scientific fact we are all 99.5 percent genetically identical. We are more alike than we are different and sometimes people forget humans have created hierarchies and caste systems. As a brand we focus on the knowledge that we are all connected, equally, through our DNA,” said Tracy Keim, Chief Brand Officer at 23andMe. “Supporting Ava DuVernay, ARRAY and the ORIGIN team by purchasing tickets for young adults through their Seat 16 program, encourages a new generation to have the opportunity to be educated through the film’s storytelling about our connection, not our differences.”

View the film's trailer . Through her foundation, 23andMe co-founder and CEO Anne Wojcicki helped fund the film along with several other non-profits.

About 23andMe

23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future. For more information, please visit .

Contacts

Media Contact: 



EN
31/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 23ANDME HLDG CO

 PRESS RELEASE

Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in...

Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale Regeneron Commits to Comply with Company’s Privacy Policy and All Applicable Law; No Changes to 23andMe’s Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO, May 19, 2025 (GLOBE NEWSWIRE) --  23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered into a definitive agreement for the sale of 23andMe to Regeneron Pharmaceuticals, Inc. (“Regeneron”) (NASDAQ: RE...

 PRESS RELEASE

23andMe Provides Update Regarding Court-Supervised Sale Process

23andMe Provides Update Regarding Court-Supervised Sale Process SAN FRANCISCO, April 18, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today provided additional information on the protections in place for customer data in connection with the court-supervised sale of the Company’s assets. The process is being led by the Special Committee of the Company’s Board of Directors, which will evaluate potential acquisition bids, and supervised by the U.S. Bankruptcy Court for the Eastern District of Misso...

 PRESS RELEASE

23andMe Confirms All Potential Buyers Must Agree to Comply With Privac...

23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law Receives Court Approval for First Day Motions to Support Ongoing Business Operations SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the “Court”) for its “first day” motions related to 23andMe’s voluntary Chapter 11 petitions filed March 23, 2025, including auth...

Pierre FerraguÊ
  • Pierre FerraguÊ

The Tech Infrastructure Quarterly Bible 4Q24

We publish today our comprehensive quarterly bible: 240 pages of detailed analyses on what happened in the last 3 months, and how we interpret it, in light of our current convictions. The first section acts as a PM summary, outlining our key findings, and latest thoughts on the semi cycle, in 6 slides.

 PRESS RELEASE

23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder...

23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Tre...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch